Barinthus Biotherapeutics plc. Cash Flow Statement
BRNS|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
Barinthus Biotherapeutics plc. used $48M in operating cash flow and negative free cash flow of $48M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.06 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$66.4M | -$73.3M | $5.3M | -$50.9M | -$17.7M |
| Depreciation & Amortization | $5.8M | $5.4M | $4.3M | $602.0K | $208.0K |
| Operating Cash Flow | -$48.0M | -$50.9M | -$14.4M | -$32.6M | -$11.0M |
| Capital Expenditures | $37.0K | $5.4M | $6.1M | $1.1M | $293.0K |
| Free Cash Flow | -$48.0M | -$56.3M | -$20.6M | -$33.7M | -$11.3M |
| FCF Margin | - | -7024.7% | -46.0% | -12585.5% | -234.8% |